Legal Status Overview
Gray AreaTexas has no statute, administrative rule, or Board of Pharmacy policy that names peptides, 'research chemicals,' or research-use-only compounds as a distinct legal category. Peptides that are FDA-approved prescription drugs (e.g., semaglutide-class products, prescribed HGH) are lawful in Texas when prescribed by a licensed practitioner and dispensed by a licensed pharmacy, and are treated as 'dangerous drugs' under the Texas Dangerous Drug Act, meaning possession, delivery, or manufacture outside that framework can be a criminal offense. Unapproved research peptides such as BPC-157 and TB-500 sit in a genuine gray zone: their compounding eligibility is determined federally under FD&C Act sections 503A/503B, not by any Texas-specific rule, and as of July 2026 an FDA advisory committee has recommended — but the FDA has not yet finalized — adding several of them to the 503A Bulks List. In short, Texas defers almost entirely to federal law and enforces through general pharmacy, compounding, and prescription-drug rules.
Key Points
- Texas has no official GLP-1 or peptide-specific pharmacy board position and instead regulates these products through its general compounding framework, which already incorporates the federal 'essentially a copy' limitation. [1]
- Like most states, Texas does not set its own substantive baseline for what may lawfully be compounded; that eligibility baseline is fixed federally by Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. [2]
- Under the Texas Dangerous Drug Act, any drug that bears or is required to bear the 'Rx only' legend is a 'dangerous drug,' which sweeps prescription peptide products such as semaglutide-class drugs and prescribed HGH into Texas prescription-drug law. [3]
- Texas Health and Safety Code Section 483.043 makes it a state jail felony to manufacture a dangerous drug when the person is not authorized by law to manufacture it, and Chapter 483 separately criminalizes unauthorized possession and delivery. [4]
- The Texas State Board of Pharmacy's non-sterile compounding rule, 22 TAC Section 291.131, sets general compounding standards and bars pharmacies from compounding any preparation containing ingredients on the FDA's list of drug products withdrawn or removed from the market for safety reasons, but contains no peptide-specific category. [5]
- The Board's most recent compounding rulemaking — amendments to 22 TAC Section 291.133 on sterile compounding, filed with the Secretary of State on February 9, 2026 — updated general personnel, environment, compounding process, beyond-use dating, sterility testing, and recordkeeping requirements rather than addressing peptides or GLP-1 products specifically. [6]
- On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax to the 503A Bulks List, but those votes are non-binding recommendations that still require formal approval before compounding pharmacies may rely on them. [7]
- Searches for Texas-specific peptide legislation, Board of Pharmacy bulletins naming peptides or 'research chemicals,' and Texas Attorney General guidance on compounded semaglutide/tirzepatide did not surface any Texas-specific authority; this point reflects the absence of located sources rather than a positive statement in any statute, and readers should verify with current TSBP and legislative records. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
Sources
Last researched: 2026-08-10